NHS
Surrey and Sussex Healthcare
NHS Trust

Trust Headquarters
East Surrey Hospital
Canada Avenue
Redhill
RH1 5RH

Tel: 01737 768511
www.sash.nhs.uk

Our ref: 4719

17 May 2018

Freedom of information request

I am writing in response to your request for information which has been handled under the Freedom of Information Act 2000 (FOIA).

1. Do you have local clinical pathways or standard operating procedures (SOPs) for the use of MabThera? If so are you able to share these? For instance, is one cycle of MabThera intravenous (IV) always used before initiating the patients on MabThera subcutaneous (SC) in oncology indications? We do not start any patients on MabThera. We only ever start patients on a biosimilar product.

2. Number of patients treated* using MabThera subcutaneous versus MabThera intravenous in oncology indications between 2016-2018, if only partial data is available please indicate the timeframe the data refers to:

Oncology		
Financial Year	Number of patients treated using **MabThera Intravenous** *(if possible, please provide number of patients excluding those who were switched to MabThera subcutaneous)*	Number of patients treated using **MabThera Subcutaneous**
FY 2016-17	193	40
FY 2017-18	148	17

**if number of patients treated is not available please provide information in units that you have available (e.g. vials, preparations…)*

3. Total number of patients treated* with MabThera (intravenous and subcutaneous) vs Rixathon vs Truxima in oncology and rheumatology indications between 2016-2018, if only partial data is available please indicate the timeframe the data refers to:

Financial Year	**Drug**	**Number of patients treated in Oncology**	**Number of patients treated in Rheumatology**

FY 2016-17	MabThera	174	59
	Truxima	0	0
	Rixathon	0	0
FY 2017-18	MabThera	79	17
	Truxima	18	51
	Rixathon		

**if number of patients treated is not available please provide information in units that you have available (e.g. vials, preparations…)*

4. Do you have local clinical pathways or standard operating procedures (SOPs) for the initiation of new patient treatment regimens? If so are you able to share these? Network guidelines – please refer to Cancer Alliance website and Surrey PAD

5. Specifically, are new patients directly prescribed biosimilar rituximab (i.e. Truxima or Rixathon) instead of MabThera? Yes

6. Are existing patients being switched from MabThera intravenous to biosimilar rituximab (i.e. Truxima or Rixathon)? If so is there a set point in their treatment pathway when patients are switched and how is this managed? Patients were switched if on episodic treatment (eg in Rheumatology). No fixed term courses were switched.

7. Are any existing patients being switched from MabThera subcutaneous to biosimilar rituximab (i.e. Truxima or Rixathon)? If so is there a set point in their treatment pathway when patients are switched and how is this managed? No

8. Number of patients treated* using rituximab biosimilars (Truxima and Rixathon) instead of MabThera (intravenous and subcutaneous) between 2016-2018, if only partial data is available please indicate the timeframe the data refers to:

Financial Year	**Drug**	**Oncology**		**Rheumatology**	
		New patients treated directly with the biosimilar instead of MabThera	**Existing patients switched from MabThera to the biosimlar**	**New patients treated directly with the biosimilar instead of MabThera**	**Existing patients switched from MabThera to the biosimlar**
FY 2016-17	Truxima				
	Rixathon				
FY 2017-18	Truxima	18		51	
	Rixathon				

**if number of patients treated is not available please provide information in units that you have available (e.g. vials, preparations…)*

9. As an organisation, are you aware of any financial savings made by using biosimilar rituximab (i.e. Truxima or Rixathon) vs MabThera between 2017-2018, if only partial data is available please indicate the timeframe the data refers to and the methods used to calculate the financial savings.

Year	**Scheme** *(e.g. discounting, gainshare…)*	**Approximate saving (£)**
2017-18	Price reduction (saving to commissioners)	£237k

10. Please provide information on the current contracts for Truxima, Rixathon, MabThera intravenous (IV) or subcutaneous (SC): We don't have a local contract for any rituximab product

Drug	**Contract value (£)***	**Volume of contract** (number of vials)	**Is price tiered by volume?** (Yes/No)	**Length of contract**		**Renewal frequency**	**Services included**	
				Date of contract initiation	**Date of contract expiry**		**Yes/No**	**Which services** *(e.g. biosimilar education, patient support program…)*
Rixathon								
Truxima								
MabThera IV								
MabThera SC								

**if the total contract value is not available, please provide the price range for each drug*

11. Related to question 10, if contracts are tiered by volume, could you please provide the thresholds for each tier and what is the price percentage difference between tiers? N/A